Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Gall Bladder Cancer

Clinical Trial at: Compass Oncology - Tigard

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

  • Details

ClinicalTrials.gov ID: NCT05506943
Diagnosis Type: Gall Bladder Cancer
USOR Number: 22147

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

  • Details

ClinicalTrials.gov ID: NCT05506943
Diagnosis Type: Gall Bladder Cancer
USOR Number: 22147

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Vancouver

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)

  • Details

ClinicalTrials.gov ID: NCT05512377
Diagnosis Type: Urothelial Cancer
USOR Number: 22123

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Tigard

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)

  • Details

ClinicalTrials.gov ID: NCT05512377
Diagnosis Type: Urothelial Cancer
USOR Number: 22123

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Portland

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)

  • Details

ClinicalTrials.gov ID: NCT05512377
Diagnosis Type: Urothelial Cancer
USOR Number: 22123

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Compass Oncology - Portland

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)

  • Details

ClinicalTrials.gov ID: NCT05512377
Diagnosis Type: Urothelial Cancer
USOR Number: 22123

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Breast Cancer

Clinical Trial at: Compass Oncology - Tigard

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Breast Cancer

Clinical Trial at: Compass Oncology - Vancouver

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Breast Cancer

Clinical Trial at: Compass Oncology - Portland

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Breast Cancer

Clinical Trial at: Compass Oncology - Portland

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page
1 2 3 4 5 6 … 13

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.